NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

NCT06439576

Active Not RecruitingN/A

Sponsor: Hoffmann-La Roche

Conditions: Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion

Interventions: Faricimab

Countries: China

The Farseeing Study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in China. It is a primary data collection, non-interventional, prospective and retrospective, multi-center study designed to collect real-world, long-term data to gain clinical evidence on faricimab, by observing cohorts of patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) who are receiving treatment with faricimab.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Have signed the informed consent
2. Female and male Chinese patients, who had been diagnosed with nAMD, DME, or RVO by CFP, OCT, FFA, ICGA, or OCTA
3. ≥50 years old for patients with nAMD, ≥18 years old both for patients with DME and RVO, at the time of signing informed consent (or the first administration of faricimab, whichever occurs first)
4. Patients for whom the decision to receive treatment with faricimab is made prior to and independent from study participation
5. Patients have received at least one faricimab treatment (the first dose) in the study eye

Exclusion Criteria:

1. Patients not receiving treatment for nAMD/DME/RVO with faricimab according to the standard of care and in line with the current summary of product characteristics (SPC) / labeling in China
2. Active ocular inflammation or suspected / active ocular infection in either eye
3. Received any other anti-VEGF treatment after faricimab
4. Received any steroid treatment within 6 months (180 days) before the first faricimab treatment in the study eye
5. Any participation in any other clinical trials currently
6. Patients could not provide the clinical data (visual acuity and OCT images) within 2 weeks (14 days) before receiving the initial faricimab injection

Locations (41)

Shantou, Guangdong, China
Luoyang, Henan, China
Shiyan, Hubei, China
Xuzhou, Jiangsu, China
Fushun, Liaoning, China
Panjin, Liaoning, China
Shenyang, Liaoning, China
Weifang, Shandong, China
Shanghai, Shanghai Municipality, China
Chengdu, Sichuan, China
Kashgar, Xinjiang Uygur, China
Kunming, Yun'nan, China
Jinhua, Zhejiang, China
Beijing, China
Chengdu, China
Dingzhou, China
Dongyang, China
Guangzhou, China
Guiyang, China
Jinan, China
Lanzhou, China
Luzhou, China
Nanjing, China
Nanning, China
Qingdao, China
Shanghai, China
Shanghai, China
Shanghai, China
Shanghai, China
Shenyang, China
+ 11 more on CT.gov